New United States Patent Protects Probiotic Innovation in All Coffee, Tea, and Cereal
Cleveland, OH (PRWEB) April 29, 2014 -- Ganeden Biotech, a recognized world leader in the manufacturing and marketing of probiotics, today announced the issuance of a United States patent that covers the use of all Bacillus coagulans in all coffee, tea and cereal.
The issuance of patent #US 8,697,055 B2 protects the use of all Bacillus coagulans probiotic strains including GanedenBC30 in coffee, tea and cereal applications. “Our patent attorneys at Mintz Levin continue to provide superior legal counsel that strengthens our market position,” said David Keller, Ganeden Biotech VP of Scientific Operations.
The probiotic industry is growing rapidly, with no indication that it will be slowing down anytime soon; by 2015 the market is expected to reach $31.1 billion globally, with about 90% of that from the sale of functional foods and beverages. In addition, consumer awareness continues to increase with over 80% of consumers associating probiotics with a health benefit. Ganeden Biotech’s goal is to make probiotics available in every-day food so that consumers don’t have to take another pill. Coffee, tea and cereal are a big part of that.
Spore forming probiotic organisms such as GanedenBC30 are the only probiotics that have the ability to withstand harsh manufacturing processes, especially those required to make hot tea, coffee and cereal. The effectiveness of these organisms can be linked to its naturally occurring layer of organic material (spore), which protects the genetic core of the bacteria throughout the manufacturing process and the transit in to the gut. Non-spore forming probiotics, such as Lactobacillus and Bifidobacterium, are unable to form this protective layer, making them much more vulnerable to manufacturing conditions.
“This patent goes a long way toward supporting our partners in their quest to launch new brands, and revolutionize existing ones,” said Andy Lefkowitz, CEO of Ganeden Biotech. “When combined with the FDA’s No Objection letter on GRAS (safety), 17 studies published in peer reviewed journals, over 100 patents issued around the world and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation.”
About Ganeden Biotech
Ganeden Biotech is at the forefront of probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, and now personal care ingredients markets. Ganeden is best known for GanedenBC30 (Bacillus coagulans GBI-30, 6086), its patented, FDA GRAS, highly stable probiotic ingredient. Ganeden's newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden Biotech and licensing opportunities visit GanedenBiotech.com.
About GanedenBC30
Introducing GanedenBC30® (Bacillus coagulans GBI-30, 6086), Ganeden Biotech’s patented probiotic ingredient that can be found in more than 100 leading food, beverage and companion animal products throughout the world. Unlike most other probiotic strains, GanedenBC30 is a spore-former which makes it highly stable and allows it remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid. The efficacy of GanedenBC30 is backed by 17 published studies showing digestive and immune support and GanedenBC30 has an exceptional safety record with FDA GRAS status from the United States FDA. It can be formulated into virtually any product that is baked, boiled, frozen or squeezed….including all hot or refrigerated beverages! For more information, please visit GanedenBiotech.com or GanedenBC30.com.
Julie Lebowitz, Ganeden Biotech, +1 440.229.5205, [email protected]
Share this article